ClinicalTrials.gg
CompletedNCT01256476PREVAIL-USUpdated May 8, 2012Results posted

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

A Phase 4 interventional study of pitavastatin and pravastatin in Primary Dyslipidemia and Mixed Dyslipidemia, sponsored by Kowa Research Institute, Inc.. Completed at 44 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-05-08.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pitavastatin in Dyslipidemias — 2 open to participants now, 3 under way, none of them phase 3. pitavastatin · Dyslipidemias.

Enrollment
10th of 21
328 · median 252
Started
2010
with 1 other
Phase 4
6 of 21
none open now
Registered
10th of 21
by date
Lead sponsor
4 of 21
Kowa Research Institute, Inc.

Among the 21 studies testing pitavastatin in Dyslipidemias, this one is the 10th largest by enrollment, is one of 2 that started in 2010, is one of 6 in phase 4, and was the 10th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

2 of the 21 studies testing pitavastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pitavastatin in Dyslipidemias, or all of them as a file.
02

Study summary

Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.

03

Conditions studied

  • Primary Dyslipidemia
  • Mixed Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with primary hypercholesterolemia or mixed dyslipidemia who are ≥18 and ≤80 years of age at the time of consent
  • Plasma Low-density lipoprotein cholesterol (LDL-C) ≥130 milligrams per deciliter (mg/dL) and ≤220 mg/dL and triglyceride (TG) levels of ≤400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • Any conditions which may cause secondary dyslipidemia
  • Uncontrolled diabetes mellitus
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    pitavastatin 4 mg once daily (QD)

    Drug: pitavastatin

  • Active comparator
    pravastatin 40 mg once daily (QD)

    Drug: pravastatin

Interventions

  • pitavastatin 4 mg once daily (QD)

    Also known as: Livalo

  • Pravastatin 40 mg once daily (QD)

06

What researchers measure

Primary outcomes

  1. Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12

    Time frame: Baseline and 12 weeks

07

Results

Posted Apr 30, 2012

Participant flow

Participant flow — Overall Study
MilestonePitavastatin 4 mg Once a Day (QD)Pravastatin 40 mg Once a Day (QD)
Started164164
Completed158157
Not completed67
Withdrew: Adverse event21
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up12
Withdrew: Persistent alt or ast elevation10
Withdrew: Physician decision01
Withdrew: Subject non-compliance01
Withdrew: Ldl-c elevation exceeding 250 mg/dl01

Outcome measures

PrimaryMean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12
Time frame:
Baseline and 12 weeks
Reported as:
Mean · percent
Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12
percentPitavastatin 4 mg Once Daily (QD)Pravastatin 40 mg Once Daily (QD)
Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12-34.8 ± 1.20-22.7 ± 1.22

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 4 mg Once a Day (QD)—2/164 (1.2%)19/164 (11.6%)
Pravastatin 40 mg Once a Day (QD)—1/164 (0.6%)14/164 (8.5%)
Most frequent serious events
Most frequent serious events
EventPitavastatin 4 mg Once a Day (QD)Pravastatin 40 mg Once a Day (QD)
appendicitis perforatedGastrointestinal disorders1/1640/164
prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1640/164
lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1641/164
Most frequent other events
Most frequent other events
EventPitavastatin 4 mg Once a Day (QD)Pravastatin 40 mg Once a Day (QD)
NasopharyngitisInfections and infestations11/1645/164
upper respiratory tract infectionInfections and infestations8/1649/164

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 4 mg Once a Day (QD)Pravastatin 40 mg Once a Day (QD)Total
<=18 years000
Between 18 and 65 years122127249
>=65 years423779
Age Continuous
Age Continuous(years)Pitavastatin 4 mg Once a Day (QD)Pravastatin 40 mg Once a Day (QD)Total
Mean58.8 ± 8.9357.0 ± 10.2357.9 ± 9.63
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 4 mg Once a Day (QD)Pravastatin 40 mg Once a Day (QD)Total
Female8379162
Male8185166
Region of Enrollment
Region of Enrollment(participants)Pitavastatin 4 mg Once a Day (QD)Pravastatin 40 mg Once a Day (QD)Total
United States164164328
08

Study locations

44 sites
  • Huntsville, Alabama, United States
  • Muscle Shoals, Alabama, United States
  • Chandler, Arizona, United States
  • Goodyear, Arizona, United States
  • Phoenix, Arizona, United States
  • Beverly Hills, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • Colorado Springs, Colorado, United States
  • Clearwater, Florida, United States
  • Deland, Florida, United States
  • Fort Luaderdale, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Ovido, Florida, United States
  • Pembroke Pines, Florida, United States
  • Ponte Vedra, Florida, United States
  • Addison, Illinois, United States
  • Chicago, Illinois, United States
  • Evansville, Indiana, United States
  • Indianapolis, Indiana, United States
  • Kansas City, Kansas, United States
  • Erlanger, Kentucky, United States
  • Baltimore, Maryland, United States
  • Brockton, Massachusetts, United States
  • Edina, Minnesota, United States
  • Las Vegas, Nevada, United States
  • Berlin, New Jersey, United States
  • Rochester, New York, United States
  • Statesville, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Lyndhurst, Ohio, United States
  • Willoughby Hills, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Eugene, Oregon, United States
  • Greer, South Carolina, United States
  • Mt. Pleasant, South Carolina, United States
  • Corpus Christi, Texas, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Olympia, Washington, United States
09

References and documents

Publications

  • Miller PE, Martin SS, Joshi PH, Jones SR, Massaro JM, D'Agostino RB, Sponseller CA, Toth PP. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. Clin Ther. 2016 Mar;38(3):603-9. doi: 10.1016/j.clinthera.2016.02.001. Epub 2016 Feb 26. Erratum In: Clin Ther. 2017 Mar;39(3):663. doi: 10.1016/j.clinthera.2017.02.003. PubMed 26922296 ↗
  • Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014 Aug 1;36(8):1211-22. doi: 10.1016/j.clinthera.2014.06.009. Epub 2014 Jul 3. PubMed 24998014 ↗
  • Chapman MJ, Orsoni A, Robillard P, Hounslow N, Sponseller CA, Giral P. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin. 2014 May;30(5):775-84. doi: 10.1185/03007995.2013.874989. Epub 2014 Jan 10. PubMed 24328357 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2010
First posted
Dec 8, 2010
Start
Oct 2010
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Apr 30, 2012
Last update
May 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01256476
Responsible party
Sponsor
First posted
Dec 8, 2010
Start date
Oct 2010
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Apr 30, 2012
Last update
May 8, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion